Join Rob Bootle as he explores his journey at Nanopharm, highlighting the company’s cutting-edge research and development in orally inhaled and nasal drug products (OINDPs). Discover the innovative approaches to nasal sprays, and learn about the significant strides being made in transitioning to environmentally friendly, low-global warming potential (GWP) propellants in pressurized metered-dose inhalers (pMDIs). Nanopharm’s commitment to advancing pharmaceutical technologies and delivering client-focused solutions is at the forefront of Rob’s discussion.

Analytical Services
Rethinking bioequivalence for nasal suspensions: Adopting an in-vitropathway with confidence
Discover how MDRS provides a regulatory-accepted alternative to clinical endpoint studies for nasal suspension bioequivalence. Learn to de-risk your ANDA pathway today.